Amanda Ewart Toland, PhD, FACMG (Mandy), is Professor and Vice Chair in the Department of Cancer Biology Genetics with a joint appointment in the Division of Human Genetics, Department of Internal Medicine at the Ohio State University (OSU). She is also co-Director of the OSU Comprehensive Cancer Center Genomics Shared Resource [GSR]. Dr. Toland received her PhD in Human Genetics from the University of Utah in the laboratory of Dr. Mark Keating where she identified the genetic cause of Williams syndrome. She completed clinical training in PhD Medical Genetics at the University of California San Francisco followed by a research postdoctoral fellowship in the laboratory of Dr. Allan Balmain before joining the faculty at OSU in 2005. Dr. Toland currently coordinates the KeraCon Immunosuppression Working Group, is a steering committee member of the ENIGMA consortium and a member of the CIMBA consortium. Related to her work with ENIGMA, she is on the ClinVar Variant Expert Curation Panel for BRCA1/BRCA2 and is a member of the BRCA Exchange Steering Committee. She is a member of the NCI PDQ Cancer Genetics Editorial Board and is a member (and future chair 2023-25) of the NIH Cancer, Heart, and Sleep Epidemiology Panel B study section. Since 2017, she has been the Associate Editor for Translational Sciences for the British Journal of Dermatology. Dr. Toland is faculty advisor for OSU Camp Kesem, a college-student run group that provides free summer camps to kids whose parents had/have a diagnosis of cancer. Although having lived in Ohio for over 15 years, Dr. Toland considers herself a “Westerner” having grown up in Washington State and completing her PhD and postdoctoral training in Utah and California respectively. Outside of the laboratory, Dr. Toland enjoys baking, hiking in Metro parks, gardening, reading, and spending time with her husband and two kids.
Summary of Research:
Dr. Toland’s laboratory studies the role of genetic variants in modifying disease risk of hereditary and sporadic cancers using a variety of in vitro, in vivo and population-based approaches. Current projects focus on the impact of germline variants on somatic mutations in breast and colon cancer, classification of variants of uncertain clinical significance in hereditary breast cancer genes, the use of polygenic risk scores in risk decision making in BRCA mutation carriers, understanding the role of OCA2 and OCA2 variants in skin cancer risk, and the identification and characterization of driver mutations in metastatic cutaneous squamous cell carcinomas. She is an author on over 180 peer-reviewed publications (NCBI My Bibliography Page).
Ewart-Toland, A, Briassouli, P, de Koning, JP, Mao, J-H, Yuan, J, Chan, F., MacCarthy-Morrogh, L, Ponder, BAJ, Nagase, H, Burns, J, Ball, S, Almeida, M, Linardopoulos, S, and Balmain A. Identification of Stk6/STK15 as a candidate modifier of cancer risk in mouse and man. Nat. Genet 34: 403-412, 2003. PMID: 12881723.
Ewart-Toland, A, Dai, Q, Gao, Y-T, Nagase, H, Dunlop, MG, Farrington, SM, Barnetson, RA, Anton-Culver, H, Peel, D, Ziogas, A, Lin, D, Miao, X, Sun, T, Ostrander, EA, Stanford, JL, Langlois, M, Chan, JM, Yuan, J, Harris, C, Bowman, E, Clayman, GL, Lippman, SM, Lee, JJ, Zheng, W, and Balmain, A. Aurora-A/STK15 T+91A is a low penetrance cancer susceptibility gene: a large meta-analysis of multiple cancer types. Carcinogenesis 26:1368-1373, 2005. PMID: 15802297.
Spearman AD, Sweet K, Zhou X-P, McLennan J, Couch FJ, Toland AE. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol 26: 5393-5400, PMC2651073.
Dworkin AM, Ridd K, Bautista D, Allain DC, Iwenofu OH, Roy R, Bastian BC, Toland AE. Germline variation controls the architecture of somatic alterations in tumors. PLoS Genet Sep 23 6(9): e100136. 2010. PMC2944791.
Skeeles LE, Fleming JL, Mahler KL, Toland AE. The impact of 3’UTR variants on differential expression of candidate cancer susceptibility genes. PLoS One 8(3):e58609, 2013. *This paper was chosen to be a top ten paper for the NCI Epidemiology and Genomics Research for 2013. http://epi.grants.cancer.gov/highlights/ PMCID:PMC3589377
Fleming JL, Gable DL, Samadzadeh-Tarighat S, Cheng L, Yu L, Gillespie JL, Toland AE. Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. PeerJ, 1:e68, 2013. PMC3642704.
Gerber MM, Hampel H, Zhou XP, Schulz NP, Suhy A, Deveci M, Çatalyürek UV, Toland AE. Allele-specific imbalance mapping at human orthologs of mouse susceptibility to colon cancer (Scc) loci. Int J Cancer 137:2323-2331, 2015.
Siekmann T, Gerber MM, Toland AE. Variants in an HDAC9 intronic enhancer plasmid impact Twist1 expression in vitro. Mamm Genome 27(3):99-110, 2016.
Gillespie J, Skeeles LE, Allain DC, Kent MN, Peters SB, Nagarajan P, Yu L, Teknos TN, Olencki T, Toland AE. MicroRNA expression profiling in metastatic cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol30:1043-1045, 2016. PMC4567970.
Yilmaz AS, Ozer HG, Gillespie JL, Allain DC, Bernhardt MN, Furlan KC, Castro LT, Peters SB, Nagarajan P, Kang SY, Iwenofu OH, Olencki T, Teknos TN, Toland AE. Differential mutation frequencies in metastastic cutaneous squamous cell carcinomas versus primary tumors. Cancer 123:1184-1193, 2017.
Ramroop JR, Gerber MM, Toland AE. Germline variants impact somatic events during tumorigenesis. Trends Genet 35(7):515-526, 2019. PMID: 31128889
Rock AN, Fisher MD, Amborski G, Allain DC, Klee V, Peters SB, Kang S, Toland AE. MicroRNA expression profiling of cutaneous squamous cell carcinomas arising in different sites. Otolaryngol Head Neck Surg 163(3):538-535, 2020. PMID: 32423289